Business Wire

Stewart Title Ltd. Announces New London Executive Office and Addition of Claims Counsel and Senior Underwriter

Del

Stewart Title Ltd., the underwriter for Stewart’s transactions in the United Kingdom, Europe and Australia announces the expansion of its London based executive office. The new office is located at 11 Haymarket, London. In addition to the new office space in London, Stewart moved to a larger facility in Norwich earlier in the year, giving them two bases of operation in the United Kingdom along with offices throughout Europe, including Milan, Bucharest, Warsaw and Prague.

In another move to accommodate growth in this region, Stewart announced the addition of two experienced members to their team, strengthening both their underwriting and claims divisions.

Ferky Azib joined Stewart as Claims Counsel and brings to the position a wealth of litigation experience having worked at a number of national law firms, including most latterly, Dentons. Ms. Azib is a member of the Property Litigation Association and a Committee Member for Women in Property.

Michael Sawyerr joined the team as Senior Development Underwriter. Mr. Sawyerr has more than seven years of experience as a title insurance underwriter having worked at both Legal and Contingency Limited and First Title Insurance.

“This expansion of our operations reflects our ongoing commitment to providing outstanding service to our clients in the UK and Europe,” said Steven Lessack, Group President, International Operations. “With the growth of our business in this region, we felt an investment in this area was required to guarantee that we can continue to deliver quick and customised title insurance solutions. We are very pleased to have added two stellar members to our European team as additional points of contact for our clients.”

Stewart’s team is known for their knowledge, supportive technology and the ability to customise title insurance policies for a wide range of real estate transactions. The company is a leader throughout Europe, specialising in facilitating cross-border transactions and solving market-specific issues with local expertise and custom underwriting, helping clients settle their transactions efficiently and with peace of mind.

About Stewart Title Ltd.

Stewart Title Ltd. is a title insurance company authorised and regulated by the Financial Conduct Authority and Prudential Regulation Authority. As a wholly owned subsidiary of Stewart Title Guaranty Company, Stewart Title Ltd. is the primary underwriter of UK, European and Australian transactions. The company’s operations are headquartered in London with offices throughout the UK, Europe and Australia. Stewart Title Ltd. delivers a host of title insurance products, streamlining the conveyancing and closing process and helping customers creatively overcome difficult title situations. More information can be found at http://www.stewarttitlelimited.com.

About Stewart

Stewart Information Services Corporation (NYSE-STC) is a global real estate services company, offering products and services through our direct operations, network of Stewart Trusted Providers™ and family of companies. From residential and commercial title insurance and closing and settlement services to specialized offerings for the mortgage industry, we offer the comprehensive service, deep expertise and solutions our customers need for any real estate transaction. At Stewart, we believe in building strong relationships – and these partnerships are the cornerstone of every closing, every transaction and every deal. Stewart. Real partners. Real possibilities.tm More information can be found at http://www.stewart.com, subscribe to the Stewart blog at http://blog.stewart.com or follow Stewart on Twitter® @stewarttitleco.

Trademarks are the property of their respective owners.

Contact information

Stewart Information Services Corporation
Rahim Balsara
Media Relations
mediarelations@stewart.com
or
Tomasz Klodowski, +48 22 255 0875
Managing Director, European Operations
tk@stewart.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 10:18:00 CESTPressemelding

The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio

Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 10:00:00 CESTPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc

Enterprise Integration Middleware Leader, Fiorano Software, Announces Release of Fiorano Platform 12.024.4.2019 09:00:00 CESTPressemelding

Fiorano Software, a leader in Integration Middleware, API Management and peer-to-peer distributed systems, announced today the release of version 12.0 of the Fiorano ESB and API Management platform. The latest release with new adapters and tools includes enhanced and optimised features to improve performance of its servers delivering a more productive SOA and API Management deployment with a significant incremental return on investment. The platform offers a unified profile to run all Fiorano Servers in a single process and ships with several new adapters including a Kafka Connector, DynamoDB, AS4Connector, SMPPSend and WebSockets. Users can now import Event Processes directly from the Dashboard and optimize CRC processes by fetching components from local repositories. The new platform provides a new HTML5 dashboard, monetisation and security policies like JWT/JWS for API Management while supporting Open API specifications, OpenId Connect and time-based accessing and quota policies alo

Aptorum Group’s Smart Pharma announces launch of its asset backed Smart Pharma token (SMPT), supported by its computational repurposed drug discovery platform Smart-ACT™24.4.2019 08:30:00 CESTPressemelding

Aptorum Group Limited (Nasdaq:APM) is excited to announce the launch and issuance of its asset backed Smart Pharma Token (“SMPT”) by its wholly owned subsidiary group, Smart Pharma group and Smart Pharmaceutical Limited Partnership (“SPLP”) targeted in May 2019. SPLP is extremely pleased to have jointly developed the SMPT token with Aenco, an affiliated blockchain development company focused on applications in the healthcare and financial sector. The SMPT token, an ERC-1404 security compliant token, is a unique token that tokenizes valuable pharmaceutical drugs and their underlying intellectual property and associated allocation of cash flows induced by continual product development and commercialization. It is the intention of the Smart Pharma group to continue to incorporate Aenco’s blockchain technology into its pharmaceutical development and commercialization processes. Relying on intellectual property derived from the Smart-ACT™ platform, Smart Pharma’s in-house new and repurposed

Aptorum Group Establishes Smart Pharma to Focus on Computational Repurposed Drug Discovery for Orphan and Unmet Diseases24.4.2019 08:30:00 CESTPressemelding

Aptorum Group Limited (Nasdaq: APM) today announced the establishment of a new subsidiary group, Smart Pharma (“SmartP”), which operates its novel computational repurposed drug discovery, modeling and validation platform, together referred to as the “Smart-ACTTM” platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005095/en/ (Photo: Business Wire) Smart-ACTTM stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets. Specifically, the Smart-ACTTM platform comprises of a network of modules and processes that simulate the effectiveness of drug molecules against diseases for outcome prediction and selection. The Smart-ACTTM platform will initially focus on the screening drug molecules for orphan diseases or unmet medical needs. To date, SmartP has, under the recently established

Aptorum Group Limited Announces Repurchase of USD13,500,000 Outstanding Convertible Bonds Due 201924.4.2019 08:15:00 CESTPressemelding

Aptorum Group Limited (NASDAQ: APM) (“Aptorum” or the “Company”), a pharmaceutical company focused on the development and commercialization of therapeutic and diagnostic technologies to tackle unmet medical needs, announced today that the Company, in a privately-negotiated transaction, repurchased all outstanding US$13,500,000 in aggregate principal amount of the 8.00 per cent. convertible bonds due 2019 (“Convertible Bonds”) from Peace Range Limited, a wholly owned subsidiary of Adamas Ping An Opportunities Fund LP, together with certain subscription right to subscribe up to the principal amount of the Bond at a US$12.17 (subject to adjustment) on or before December 17, 2019 (“Subscription Right”). The total consideration of the repurchase of the Convertible Bonds and the Subscription Right was US$13.6 million in cash, excluding accrued interest. The repurchase of the Convertible Bonds and Subscription Right was executed by Aptorum Investment Holding Limited, a wholly owned subsidiary